TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a cytological or histological diagnosis of stage IA non-cell lung cancer diagnosed in accordance with Dutch CBO guidelines \[2004\]. When no pathological diagnosis is available, a patient with a new or growing pulmonary lesion with radiological features consistent with malignancy AND a lesion showing uptake on a FDG-PET scan will be eligible \[Herder 2005\].~* No evidence of regional or distant metastases on a standardized FDG-PET scan within 6 weeks of any protocol treatment .~* The medial extension of tumors should be least 2 cm away from main and lobar bronchi, and also minimum of 1.5 cm from large peripheral blood vessels such as the aorta and main pulmonary artery. Lesions of at least 2 cm from the mediastinal pleura will be eligible if the responsible radiation oncologist judges that the specified normal tissue tolerance doses specified in the protocol will not be exceeded.~* Patients who are judged by a multi-disciplinary team to have 2 primary lung tumors (on the basis of clinical, radiological, FDG-PET and/or cyto-pathology findings) are eligible for randomization provided that both surgery and SRT can be performed in accordance with protocol requirements.~* Patient should be fit to undergo a complete surgical resection of the lesion in accordance with Dutch CBO guidelines \[2004\]~* Performance score of ECOG ≤ 2 before any treatment.~* Able to comply with post-treatment follow-up~* Patients must sign and date a written Independent Ethics Committee approved informed consent form.~Exclusion Criteria:~* Prior chemotherapy or radiotherapy for the present diagnosis of NSCLC.~* History of any active malignancy (other than NSCLC) unless treated more than 3 years with curative intent and no recurrence, with the exception of non-melanoma skin cancers or in-situ cervical cancers.~* Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, severe cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease).~* Concomitant treatment with any other experimental drug under investigation.~* Pregnancy~* Men and women of child-bearing potential not using effective means of contraception for 6 months after treatment has been completed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- primary surgery (Type: ACTIVE_COMPARATOR): primary surgical resection
- stereotactic radiotherapy (Type: EXPERIMENTAL): primary stereotactic radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Rehabilitation of Heart Failure Patients by Telemedicine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with a dysfunction of left ventricle with ejection fraction of left ventricle \< 40 % appreciated by echocardiogram at hospital discharge for cardiac rehabilitation.~Exclusion Criteria:~* Patient non authorized to follow an effort training~* Therapeutic education impossible~* Pregnant woman or breast-feeding~* No assent~* Incapacity to use the terminal~* Minor patient or under supervision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Program of cardiac rehabilitation introduced in complete hospitalization pursued in day hospital during 3 months
- telemedicine (Type: EXPERIMENTAL): Program of cardiac rehabilitation introduced in complete hospitalization pursued at home via a terminal during 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Value of Three Dimensional Echocardiography in Congenital Cardiac Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All children requiring general anesthesia for congenital heart surgery and in whom informed parental consent has been obtained~Exclusion Criteria:~* Children with congenital heart disease who do not require heart surgery

- Gender: ALL
- Minimum Age: 5 Hours
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Meningioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed meningioma that has progressed or recurred following surgical resection and radiotherapy~* Evidence of residual tumor by MRI scan performed within two weeks prior to study entry~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* Hemoglobin at least 9 g/dL~* WBC at least 2000/mm3~* Platelet count at least 50,000/mm3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No chronic heart failure~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No serious lung disease, such as chronic obstructive pulmonary disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study~* No active infection~* No other serious concurrent disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulatory agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~* At least 4 weeks since prior therapy with mifepristone and recovered~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from prior surgery~Other:~* Prior cytodifferentiating agent allowed~* No prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Costs Realized After Percutaneous Coronary intervenTion Employing Same Day Discharge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients who undergo elective or low-risk, (i.e., in the setting of unstable angina but not non-ST segment elevation myocardial infarction) urgent PCI.~* No sociodemographic factors that would preclude SDD (prohibitive factors include no family member/friend available to remain with patient until nurse phone call the following day, no working phone, no reliable transportation, home \> 60 minutes from medical infrastructure, unable to obtain/pay for medications).~* PCI procedures performed between 08/04/14 and 08/03/16.~* Short term risk of in-hospital death, transfusion or contrast-induced nephropathy during the index hospitalization at or below 1% using Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) PCI registry risk prediction models.~* No in-lab complications (prolonged angina, acute closure, no reflow, significant or untreated dissection, vessel perforation, side branch occlusion, rescue glycoprotein IIb/IIIa inhibitor use, ventricular tachycardia or fibrillation requiring cardioversion/defibrillation, tamponade, pulmonary edema, stroke or transient ischemic attack, shock).~* Contrast Volume/Calculated Creatinine Clearance ratio \< 3~* No recurrent chest pain, shortness of breath, hemodynamic instability, bleeding or vascular complications during 6 hours in recovery area post-PCI~Exclusion Criteria:~* Use of rotational atherectomy~* Use of a glycoprotein IIb/IIIa inhibitor infusion post-PCI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Same day discharge (Type: EXPERIMENTAL): Patients who experienced uncomplicated PCI as well as an uncomplicated 6-hour observation period, will be randomly assigned to same day discharge.
- Overnight stay standard care (Type: OTHER): Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care in Texas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* be aged 18-24 at the time of enrollment; and~* not have received mental health services in the past 90 days, excluding medication;~* English-speaking, and~* screen positive for suicidal ideation.~Exclusion Criteria:~* are actively suicidal~* have a developmental disability that would preclude them from participating in the study intervention or~* who are impaired due to psychosis, mania, or substance use that would prevent them from providing consent.~* Participants will also be excluded at YST-III sites if they are unable to identify a minimum of one support person to participate in the intervention with them.~Those who are excluded will be provided with referrals for treatment services.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Suicidal Teens Accessing Treatment - Primary Care (STAT-PC) (Type: EXPERIMENTAL): This group will undergo a brief, suicide prevention intervention based on motivational interviewing that focuses on mental health care seeking behavior, problem-solving, and referrals plus brief case management
- Youth-Nominated Support Team (YST-III) (Type: EXPERIMENTAL): This group will undergo a brief, suicide prevention intervention originally developed for youth who have been psychiatrically hospitalized due to a suicide attempt or suicidal ideation that has been adapted

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Church, Extension and Academic Partners Empowering Healthy Families

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a parent or primary caregiver and child (age 6-10) dyad living in the same household~* English-speaking~Exclusion Criteria:~* Parent does not have a child between the ages of 6 and 11~* Target child does not live or spend significant time with parent/caregiver~* non-English speaking

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Children, Healthy Families+ (HCHF+) (Type: EXPERIMENTAL): HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
- MoneySmart (Type: ACTIVE_COMPARATOR): A financial education program available through the Federal Deposit Insurance Corporation. Money Smart includes programs for adults and school-aged children, a parent/caregiver guide and a train-the-trainer program. MoneySmart is an Extension-approved program designed to improve money-management practices and financial confidence for parents MoneySmart involves eight weekly sessions that includes one-to-two hour modules with take-home guides for adults. For children, there are eight sessions that include take-home worksheets and a parent/caregiver guide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endomina as an Aid for Endoscopic Full Thickness Resection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Lesion untreatable with standard technique.~2. Age between 18-65 years;~3. Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study specific procedures such as: clinical assessment, endoscopy, radiography, as well as laboratory investigations;~4. Must be able to understand and be willing to provide written informed consent;~5. Must live within 75 km of the treatment site;~Exclusion Criteria:~1. Achalasia and any other esophageal motility disorders (for upper GI lesion)~2. Severe esophagitis (for upper GI lesion)~3. Gastro-duodenal ulcer (for upper GI lesion)~4. Severe renal, hepatic, pulmonary disease or cancer;~5. GI stenosis or obstruction;~6. Pregnancy, breastfeeding or willing to become pregnant in the coming 18 months;~7. Anticoagulant therapy;~8. Impending gastric surgery 60 days post intervention (Upper GI);~9. Currently participating in other study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Suturing system with suture apposition then bulging formation then cutting the lesion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ECOG performance status of 0 or 1~* Histological documentation of adenocarcinoma of the colon or rectum. The primary site must have been confirmed to be in the large bowel~Exclusion Criteria:~* Prior systemic anticancer therapy for mCRC~* Prior hepatic surgery, chemoembolization, hepatic artery infusion, radiofrequency ablation or cryotherapy for liver metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Medical Results of Testicular Sperm Extraction by Conventional Surgery and Microsurgical Track

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 2 consecutive spermograms (with ±3 months interval) confirming absence of sperm (azoospermia)~* diagnosis of non-obstructive azoospermia on the basis of a complete history, physical examination, endocrine profile, ultrasound and chromosomal analysis~Exclusion Criteria:~* History of previous testicular surgery, except orchiopexy for undescended testis.~* Monochordy~* Ultrasound revealed testicular nodule~* Y chromosome microdeletions type AZFa and b.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- conventional TESE (Type: ACTIVE_COMPARATOR): Conventional multiple TESE is performed under general or locoregional anesthesia. Through a small vertical incision in the median scrotal raphe, the skin, dartos muscle, and tunica vaginalis are opened to expose the tunica albuginea. The tunica albuginea is ordinarily incised for about 4 mm at the medium region of the testis. A similar biopsy will be systematically performed in the contralateral testis. The biopsy is analyzed by the biologist in the theatre in order to precise if sufficient spermatozoa is retrieved.
- micro TESE (Type: EXPERIMENTAL): Microdissection TESE is also performed under general or locoregional anesthesia. After the tunica albuginea is opened widely along the antiepididymal border, direct examination of the testicular parenchyma is performed under the operating microscope. An attempt is made to identify individual seminiferous tubules that are larger, more opaque and whiter than other tubules in the testicular parenchyma, which are considered to contain spermatozoa. The extracted tubules are analyzed by the biologist in the theatre. The procedure is terminated when sperm are retrieved or further biopsy is thought likely to jeopardize the blood supply of the testis. If all tubules are seen to have an identical morphological appearance, at least three samples (upper, middle, and lower) are obtained. A similar microTESE will be systematically performed in the contralateral testis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dopamine in Orthostatic Tolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Upright plasma norepinephrine \> 600 pg/ml, or~* An increase in heart rate of \> 30 beats per minute upon standing, and~* Withdrawal of all medications for at least 3 days, and~* No associated medical illness, and~* Age 18 - 60 years old.~Exclusion Criteria:~* Older than 60 years of age~* Routinely taking medications affecting the autonomic nervous system~* Any chronic illness (cardiac, pulmonary, endocrine, gastrointestinal, rheumatologic) other than POTS~* Anemia (Hct \< 30)~* Women of childbearing age who are pregnant or nursing~* Unable to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): 10 mEq/day dietary sodium
- B (Type: EXPERIMENTAL): 150 mEq/day dietary sodium
- C (Type: EXPERIMENTAL): 300 mEq/day dietary sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 18 years old.~* Undergoing whole brain radiation therapy, using lateral opposed fields~* Total planned radiation prescription dose between 30 Gy and 37.5 Gy in 10 to 15 treatments.~Exclusion Criteria:~* Current complete or near-complete alopecia (natural or chemotherapy-induced)~* Concurrent or sequential chemotherapy with an agent known to commonly cause alopecia (Adriamycin, Cytoxan, Ifosfamide, Taxol (greater than 50 mg/m2), or Vincristine).~* Previous Radiation to the Scalp~* Any active dermatologic disease affecting the scalp, or temporal arteritis~* History of severe headaches.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Compression Headband (Type: EXPERIMENTAL): a compression headband, placed only at the time of irradiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility